Provention Bio Inc. (PRVB) shares were up 4.73% at $8.63 as of the most recent pre-market check, after regulatory approval received by the biopharmaceutical business.
PRVB received approval for what?
The Biologics License Application (BLA) for TZIELD (teplizumab-mzwv) has been authorized by the US Food and Drug Administration (FDA), according to a statement from Provention Bio (PRVB).
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
As the first and only immunomodulatory therapy to postpone the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older with stage 2 T1D, Provention Bio’s medication is an anti-CD3-directed antibody for intravenous administration. The TN-10 trial’s most frequent side effects throughout treatment and for 28 days following the final study medication administration were lymphopenia, rash, leukopenia, and headache.
PRVB viewed it as a historic moment for the T1D community and a paradigm-shifting development for those with Stage 2 T1D who are 8 years of age or older and now have a medication that has been licensed by the FDA to postpone the beginning of Stage 3 illness. One cannot overstate how valuable a delay at the beginning of Stage 3 T1D may be from the perspective of the patient and family; more time to live without and, if required, prepare for the costs, problems, and dangers associated with Stage 3 illness.
T1D can proceed in a very difficult way; patients who go from Stage 2 to Stage 3 T1D may have diabetic ketoacidosis, which can be fatal and is present in up to 50% of Stage 3 patients. Once insulin-producing cells are no longer able to maintain normal glycemic control, Stage 3 T1D can become irreversible. In only one year, a patient may require 1,460 finger sticks to check blood glucose levels, around 1,100 insulin injections, and an average of 127 episodes of hypoglycemia.
PRVB’s previous efforts:
PRVB announced a co-promotion deal with Sanofi in October 2022 for the U.S. release of TZIELD for the postponement of the onset of clinical T1D in at-risk persons. The diabetic community has won a significant and long-awaited triumph with the approval. Provention Bio (PRVB) remains committed to providing patients with the first-ever disease-modifying treatment for T1D. Sanofi’s existing infrastructure and endocrinology knowledge are now available to PRVB, enabling it to provide for the needs of people all throughout the United States.